Pfizer's Xianweiying to Transform China's Weight Management Market

China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults. This market is expected to be worth billions. The drug, licensed from Sciwind Biosciences, marks a major step in Pfizer's strategy in China. It is also approved for treating Type II diabetes.

China has officially approved Pfizer's innovative GLP-1 treatment, Xianweiying, aimed at long-term weight management for adults struggling with overweight issues or obesity. The approval marks a significant milestone in the competitive weight management market, predicted to grow immensely in the coming years.

Xianweiying, or ecnoglutide, is part of the emerging class of GLP-1 receptor agonist drugs already popular in the Chinese market, dominated by pharmaceutical giants such as Novo Nordisk, Eli Lilly, and Innovent Biologics. In February, Pfizer secured mainland China commercialization rights from Chinese biotech company, Sciwind Biosciences, underscoring a strategic move within the global metabolic field.

Despite the buzz, a concrete launch date and pricing details remain undisclosed by Pfizer. Meanwhile, sales of rival products indicate robust market potential, with substantial profits recorded on major e-commerce platforms like Alibaba's Tmall and JD.com.

(With inputs from agencies.)